search
Back to results

Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial) (BETTER)

Primary Purpose

Kidney Transplant Rejection

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Belatacept
Everolimus
mycophenolate mofetil
corticosteroids
rabbit antithymocyte globulin
Sponsored by
University of Cincinnati
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Kidney Transplant Rejection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria

  1. Male and female patients ≥ 18 years of age.
  2. Patient who is receiving a renal transplant from a living or heart-beating deceased donor.
  3. Female patients of child bearing potential must have a negative urine or serum pregnancy test within the past 48 hours prior to study inclusion.
  4. The patient has given written informed consent to participate in the study

Exclusion criteria

  1. Patient has previously received an organ transplant other than a kidney.
  2. Patient is receiving an HLA identical living donor transplant.
  3. Patient who is a recipient of a multiple organ transplant.
  4. Patient has a most recent cytotoxic PRA of >25% or calculated PRA >50% where multiple moderate level HLA antibodies exist and in the opinion of the PI represents substantial HLA sensitization.
  5. Patient with a positive T or B cell crossmatch that is primarily due to HLA antibodies.
  6. Patient with a donor specific antibody (DSA) as deemed by the PI to be associated with significant risk of rejection.
  7. Patient has received an ABO incompatible donor kidney.
  8. The deceased donor and/or deceased donor kidney meet any of the following extended criteria for organ donation (ECD):

    1. Donor age ≥ 60 years OR
    2. Donor age 50-59 years and 1 of the following:

    i. Cerebrovascular accident (CVA) + hypertension + SCr > 1.5 mg/dL OR ii. CVA + hypertension OR iii. CVA + SCr > 1.5 mg/dL OR iv. Hypertension + SCr > 1.5 mg/dL OR c. CIT ≥ 24 hours, donor age > 10 years OR d. Donation after cardiac death (DCD)

  9. Recipients will be receiving a dual or en bloc kidney transplant.
  10. Donor anticipated cold ischemia is > 30 hours.
  11. Recipient that is seropositive for hepatitis C virus (HCV) with detectable Hepatitis C viral load are excluded. HCV seropositive patients with a negative HCV viral load testing may be included.
  12. Recipients receiving a kidney from a donor with HCV viremia (detected through nucleic acid testing or other means)
  13. Recipients with a positive hepatitis B viral load or positive hepatitis B surface antigen testing within 1 year of consent.
  14. Hepatitis B surface antibody negative recipients receiving a kidney from a donor seropositive for hepatitis B core antibody or hepatitis B nucleic acid.
  15. Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV).
  16. Recipient who is seronegative for Epstein Barr Virus (EBV)
  17. Patient has uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives.
  18. Patients with thrombocytopenia (PLT <75,000/mm3), and/or leukopenia (WBC < 2,000/mm3), or anemia (hemoglobin < 6 g/dL) prior to study inclusion.
  19. Patient is taking or has been taking an investigational drug in the 30 days prior to transplant.
  20. Patient who has undergone desensitization therapy within 6 months prior to transplant.
  21. Patient has a known hypersensitivity to belatacept, tacrolimus, mycophenolate mofetil/mycophenolic acid, everolimus, rabbit anti-thymocyte globulin, or glucocorticoids.
  22. Patient is receiving chronic steroid therapy at the time of transplant.
  23. Patients with a history of cancer (other than non-melanoma skin cell cancers cured by local resection) within the last 5 years, unless they have an expected disease-free survival of >95%.
  24. Patient is pregnant, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by positive human Chorionic Gonadotropin (hCG) laboratory test.
  25. Women of childbearing potential must use reliable contraception simultaneously, unless they are status post bilateral tubal ligation, bilateral oophorectomy, or hysterectomy.
  26. Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator.
  27. Inability to cooperate or communicate with the investigator.

Sites / Locations

  • The Christ HospitalRecruiting
  • University of CincinnatiRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Group D Bela/EVR

Group E Bela/MMF

Arm Description

rATG induction/belatacept/everolimus/early steroid withdrawal rATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) Everolimus started within 24hours at 2mg BID and dosed to level 3-8ng/ml

rATG induction/belatacept/mycophenolate/chronic steroidsrATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) and then 5mg po daily thereafter MMF 1gm BID started pre-op and then continued throughout study

Outcomes

Primary Outcome Measures

Composite endpoint of patient death, graft loss, or eGFR (MDRD) < 45ml/min mL/min/1.73m2
Number of subjects with composite endpoint of either patient death, graft loss, or eGFR (MDRD) < 45 mL/min/1.73m2 at Month 12 post-transplantation compared to historical controls of the BEST Trial (groups B and C).

Secondary Outcome Measures

Incidence of Biopsy-proven acute rejection (BPAR) by Banff 2007 criteria stratified by type (ACR, AMR, or Mixed rejection)
To evaluate, by treatment group at 12 and 24 months incidence of various rejection types
Incidence of graft survival censored by patients who died with functioning graft
Incidence of death-censored graft survival not including any patients who died with their graft still functioning
# of Patients with eGFR (MDRD) < 30 mL/min/1.73m2
# of subjects with eGFR (MDRD) < 30 mL/min/1.73m2
# Patients with development of de novo donor specific antibody (DSA)
Patients with development of de novo donor specific antibody (DSA) after transplant
Composite endpoint of patient death, graft loss, or estimated eGFR (MDRD) < 45 mL/min/1.73m2 at Month 24 post-transplantation
Composite endpoint of patients with either death, graft loss, or estimated eGFR (MDRD) < 45 mL/min/1.73m2 at Month 24 post-transplantation
# Patients with Incidence of Infections
Incidence of infections, including CMV and BK virus

Full Information

First Posted
June 29, 2020
Last Updated
April 14, 2021
Sponsor
University of Cincinnati
search

1. Study Identification

Unique Protocol Identification Number
NCT04849533
Brief Title
Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)
Acronym
BETTER
Official Title
A Randomized, Multicenter Study of Belatacept, Everolimus, rATG and Early Steroid Withdrawal Versus Belatacept, Mycophenolate, rATG and Chronic Steroids in Renal Transplantation
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Recruiting
Study Start Date
April 9, 2021 (Actual)
Primary Completion Date
July 2023 (Anticipated)
Study Completion Date
July 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Cincinnati

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to determine the safety and efficacy of two calcineurin inhibitor free treatment groups 1) a belatacept, everolimus and early corticosteroid withdrawal (ECSWD) immunosuppressive regimen with rabbit antithymocyte globulin induction (rATG) and 2) a belatacept, mycophenolate, chronic steroid regimen with rATG and compare to historical controls of tacrolimus-based and belatacept-based regimens in combination with rATG induction, mycophenolate, and ESWD in renal transplant recipients. The purpose is to evaluate the effect of 2 regimens (rATG induction/belatacept/everolimus/ESWD and rATG induction/belatacept/mycophenolate/CS) on the composite of patient death, graft loss, or eGFR (MDRD) < 45 mL/min/1.73m2 at Month 12 post-transplantation compared to historical controls of the BEST Trial (groups B and C).
Detailed Description
The BETTER trial is designed to determine the safety and efficacy of two calcineurin inhibitor free treatment groups 1) a belatacept, everolimus and early corticosteroid withdrawal (ESWD) immunosuppressive regimen with rabbit antithymocyte globulin induction (rATG) and 2) a belatacept, mycophenolate, chronic steroid regimen with rATG and compare to historical controls of tacrolimus-based and belatacept-based regimens in combination with rATG induction, mycophenolate, and ESWD in renal transplant recipients. Study Hypotheses A belatacept-based immunosuppressive regimen with rATG induction, everolimus and ESWD in renal transplant recipients will lead to less risk of graft loss, patient death, or eGFR <45ml/min/1.73m2 at 12 and 24 months as compared to a tacrolimus-based immunosuppressive regimen with rATG, mycophenolate, and ESWD in renal transplant recipients (historical control from the BEST Trial-Group C). A belatacept-based immunosuppressive regimen with rATG induction, everolimus and ESWD in renal transplant recipients will lead to less risk of graft loss, patient death, or eGFR <45ml/min/1.73m2 at 12 and 24 months as compared to a belatacept-based immunosuppressive regimen with rATG and mycophenolate, and ESWD in renal transplant recipients (historical control from the BEST Trial-Group B). A belatacept-based immunosuppressive regimen with rATG, mycophenolate and CS in renal transplant recipients will lead to less risk of graft loss, patient death, or eGFR <45ml/min/1.73m2 at 12 and 24 months as compared to a tacrolimus-based immunosuppressive regimen with rATG, mycophenolate, and ESWD in renal transplant recipients (historical control from the BEST Trial-Group C). A belatacept-based immunosuppressive regimen with rATG induction, mycophenolate and CS in renal transplant recipients will lead to less risk of graft loss, patient death, or eGFR <45ml/min/1.73m2 at 12 and 24 months as compared to a belatacept-based immunosuppressive regimen with rATG, mycophenolate, and ESWD in renal transplant recipients (historical control from the BEST Trial-Group B). A controlled, randomized group study is accepted in renal transplantation to evaluate new immunosuppressive regimens versus the current standard of care. Although the ideal study would employ a blinded methodology with a simultaneous control group to minimize bias, the study will not be blinded and evaluates a historical control groups conducted in similar centers. To allow comparison between studies, the primary composite endpoint of death, graft loss, or eGFR <45ml/min/1.73m2 will be analyzed similarly. The secondary and tertiary endpoints are the similar as well. The BETTER study proposes to compare two additional treatment groups of rATG/belatacept/everolimus/ESWD (Group D) and rATG/belatacept/mycophenolate/CS (Group E) to the historical control Groups B and C. All immunosuppressive agents are approved by the FDA for the prophylaxis of renal transplant rejection, and will be dosed and administered consistent with current clinical practice.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kidney Transplant Rejection

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group D Bela/EVR
Arm Type
Experimental
Arm Description
rATG induction/belatacept/everolimus/early steroid withdrawal rATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) Everolimus started within 24hours at 2mg BID and dosed to level 3-8ng/ml
Arm Title
Group E Bela/MMF
Arm Type
Active Comparator
Arm Description
rATG induction/belatacept/mycophenolate/chronic steroidsrATG 1.5mg/kg IV X 4 doses over 10 days belatacept 10mg/kg IV X 1 on POD 1, POD 5, weeks 2, 4, 8, and 12 then 5mg/kg IV X 1 on week 16 and then every 4 weeks thereafter Steroid taper x 5 days (500mg IV, 250mg IV, 125mg IV, 80mg po, 60mg po) and then 5mg po daily thereafter MMF 1gm BID started pre-op and then continued throughout study
Intervention Type
Drug
Intervention Name(s)
Belatacept
Other Intervention Name(s)
Nulojix
Intervention Description
belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
Intervention Type
Drug
Intervention Name(s)
Everolimus
Other Intervention Name(s)
Zortress
Intervention Description
belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
Intervention Type
Drug
Intervention Name(s)
mycophenolate mofetil
Other Intervention Name(s)
Cellcept
Intervention Description
belatacept with mycophenolate is approved regimen for prevention of rejection
Intervention Type
Drug
Intervention Name(s)
corticosteroids
Other Intervention Name(s)
Prednisone
Intervention Description
belatacept with chronic steroids is approved regimen for prevention of rejection
Intervention Type
Drug
Intervention Name(s)
rabbit antithymocyte globulin
Other Intervention Name(s)
rATG, thymoglobulin
Intervention Description
rabbit antithymocyte globulin induction for prevention of rejection
Primary Outcome Measure Information:
Title
Composite endpoint of patient death, graft loss, or eGFR (MDRD) < 45ml/min mL/min/1.73m2
Description
Number of subjects with composite endpoint of either patient death, graft loss, or eGFR (MDRD) < 45 mL/min/1.73m2 at Month 12 post-transplantation compared to historical controls of the BEST Trial (groups B and C).
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Incidence of Biopsy-proven acute rejection (BPAR) by Banff 2007 criteria stratified by type (ACR, AMR, or Mixed rejection)
Description
To evaluate, by treatment group at 12 and 24 months incidence of various rejection types
Time Frame
12 and 24 months
Title
Incidence of graft survival censored by patients who died with functioning graft
Description
Incidence of death-censored graft survival not including any patients who died with their graft still functioning
Time Frame
12 and 24 months
Title
# of Patients with eGFR (MDRD) < 30 mL/min/1.73m2
Description
# of subjects with eGFR (MDRD) < 30 mL/min/1.73m2
Time Frame
12 and 24 months
Title
# Patients with development of de novo donor specific antibody (DSA)
Description
Patients with development of de novo donor specific antibody (DSA) after transplant
Time Frame
12 and 24 months
Title
Composite endpoint of patient death, graft loss, or estimated eGFR (MDRD) < 45 mL/min/1.73m2 at Month 24 post-transplantation
Description
Composite endpoint of patients with either death, graft loss, or estimated eGFR (MDRD) < 45 mL/min/1.73m2 at Month 24 post-transplantation
Time Frame
24 months
Title
# Patients with Incidence of Infections
Description
Incidence of infections, including CMV and BK virus
Time Frame
12 and 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria Male and female patients ≥ 18 years of age. Patient who is receiving a renal transplant from a living or heart-beating deceased donor. Female patients of child bearing potential must have a negative urine or serum pregnancy test within the past 48 hours prior to study inclusion. The patient has given written informed consent to participate in the study Exclusion criteria Patient has previously received an organ transplant other than a kidney. Patient is receiving an HLA identical living donor transplant. Patient who is a recipient of a multiple organ transplant. Patient has a most recent cytotoxic PRA of >25% or calculated PRA >50% where multiple moderate level HLA antibodies exist and in the opinion of the PI represents substantial HLA sensitization. Patient with a positive T or B cell crossmatch that is primarily due to HLA antibodies. Patient with a donor specific antibody (DSA) as deemed by the PI to be associated with significant risk of rejection. Patient has received an ABO incompatible donor kidney. The deceased donor and/or deceased donor kidney meet any of the following extended criteria for organ donation (ECD): Donor age ≥ 60 years OR Donor age 50-59 years and 1 of the following: i. Cerebrovascular accident (CVA) + hypertension + SCr > 1.5 mg/dL OR ii. CVA + hypertension OR iii. CVA + SCr > 1.5 mg/dL OR iv. Hypertension + SCr > 1.5 mg/dL OR c. CIT ≥ 24 hours, donor age > 10 years OR d. Donation after cardiac death (DCD) Recipients will be receiving a dual or en bloc kidney transplant. Donor anticipated cold ischemia is > 30 hours. Recipient that is seropositive for hepatitis C virus (HCV) with detectable Hepatitis C viral load are excluded. HCV seropositive patients with a negative HCV viral load testing may be included. Recipients receiving a kidney from a donor with HCV viremia (detected through nucleic acid testing or other means) Recipients with a positive hepatitis B viral load or positive hepatitis B surface antigen testing within 1 year of consent. Hepatitis B surface antibody negative recipients receiving a kidney from a donor seropositive for hepatitis B core antibody or hepatitis B nucleic acid. Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV). Recipient who is seronegative for Epstein Barr Virus (EBV) Patient has uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives. Patients with thrombocytopenia (PLT <75,000/mm3), and/or leukopenia (WBC < 2,000/mm3), or anemia (hemoglobin < 6 g/dL) prior to study inclusion. Patient is taking or has been taking an investigational drug in the 30 days prior to transplant. Patient who has undergone desensitization therapy within 6 months prior to transplant. Patient has a known hypersensitivity to belatacept, tacrolimus, mycophenolate mofetil/mycophenolic acid, everolimus, rabbit anti-thymocyte globulin, or glucocorticoids. Patient is receiving chronic steroid therapy at the time of transplant. Patients with a history of cancer (other than non-melanoma skin cell cancers cured by local resection) within the last 5 years, unless they have an expected disease-free survival of >95%. Patient is pregnant, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by positive human Chorionic Gonadotropin (hCG) laboratory test. Women of childbearing potential must use reliable contraception simultaneously, unless they are status post bilateral tubal ligation, bilateral oophorectomy, or hysterectomy. Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator. Inability to cooperate or communicate with the investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rita R Alloway, PharmD
Phone
5135581568
Email
rita.alloway@uc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Adele R Shields, PharmD
Phone
5135852145
Email
adele.rike@uc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rita R Alloway, PharmD
Organizational Affiliation
University of Cincinnati
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Christ Hospital
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adele R Shields, PharmD
Phone
513-585-2145
Email
adele.rike@uc.edu
First Name & Middle Initial & Last Name & Degree
Samantha Simmons
Phone
5135850016
Email
dentonsa@ucmail.uc.edu
Facility Name
University of Cincinnati
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rita R Alloway, PharmD
Phone
513-558-1568
Email
rita.alloway@uc.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)

We'll reach out to this number within 24 hrs